Drugs / ADP-A2M10
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02989064 | Oct 2016 → Dec 2019 | head and neck cancer, melanoma, urothelial carcinoma | Adaptimmune | Completed | No outcome recorded |
| Phase 1 | NCT02592577 | Nov 2015 → Mar 2020 | non-small cell lung carcinoma | Adaptimmune | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADP-A2M10 | “ADP-A2M10 specific peptide enhanced affinity receptor (SPEAR) T-cells are genetically engineered autologous T-cells that express a high-affinity melanoma-associated antigen...” PMID 35372008 ↗ Mar 20221“Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10(+) advanced non-small cell lung cancer.” PMID 35086946 ↗ Jan 2022 |
| Action | Deplete | “The changed T cells used in this study will be the subject's own T cells that have been genetically changed with the aim of attacking and destroying cancer cells.” NCT02592577 ↗ |
| Modality | Cell therapy | “ADP-A2M10 specific peptide enhanced affinity receptor (SPEAR) T cells (ADP-A2M10) are genetically engineered autologous T cells” PMID 35086946 ↗ Jan 2022 |
| Route | Other | “followed by the T cell infusion” NCT02592577 ↗ |
| Target | MAGEA10 | “TCR targeting MAGE-A10” PMID 35086946 ↗ Jan 2022 |